These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 30704657)

  • 41. Bone mineral density screening and its accordance with Canadian clinical practice guidelines from 2000-2013: an unchanging landscape in Saskatchewan, Canada.
    McLeod KM; Johnson S; Charturvedi R; St Onge J; Lionel A; Verma A
    Arch Osteoporos; 2015; 10():227. PubMed ID: 26173601
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ten-year absolute fracture risk and hip bone strength in Canadian women with systemic lupus erythematosus.
    Lee JJ; Aghdassi E; Cheung AM; Morrison S; Cymet A; Peeva V; Neville C; Hewitt S; DaCosta D; Pineau C; Pope J; Fortin PR
    J Rheumatol; 2012 Jul; 39(7):1378-84. PubMed ID: 22660811
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Osteoporosis Clinical Guideline. South African Medical Association--Osteoporosis Working Group.
    Hough S
    S Afr Med J; 2000 Sep; 90(9 Pt 2):907-44. PubMed ID: 11081144
    [TBL] [Abstract][Full Text] [Related]  

  • 44. US Preventative Services Task Force FRAX threshold has a low sensitivity to detect osteoporosis in women ages 50-64 years.
    Bansal S; Pecina JL; Merry SP; Kennel KA; Maxson J; Quigg S; Thacher TD
    Osteoporos Int; 2015 Apr; 26(4):1429-33. PubMed ID: 25614141
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bone: bone density screening leads to reduced fracture risk.
    Watts NB
    Nat Rev Endocrinol; 2010 Jan; 6(1):17-8. PubMed ID: 20010967
    [No Abstract]   [Full Text] [Related]  

  • 46. [Osteoporosis screening--indications for bone densitometry].
    Pfister J; Gerber H
    Schweiz Rundsch Med Prax; 1994 Aug; 83(35):969-74. PubMed ID: 7939050
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rationale of the Spanish FRAX model in decision-making for predicting osteoporotic fractures: an update of FRIDEX cohort of Spanish women.
    Azagra R; Zwart M; Encabo G; Aguyé A; Martin-Sánchez JC; Puchol-Ruiz N; Gabriel-Escoda P; Ortiz-Alinque S; Gené E; Iglesias M; Moriña D; Diaz-Herrera MA; Utzet M; Manresa JM;
    BMC Musculoskelet Disord; 2016 Jun; 17():262. PubMed ID: 27317560
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Application of the WHO fracture risk assessment tool (FRAX) to predict need for DEXA scanning and treatment in patients with inflammatory bowel disease at risk of osteoporosis.
    Goodhand JR; Kamperidis N; Nguyen H; Wahed M; Rampton DS
    Aliment Pharmacol Ther; 2011 Mar; 33(5):551-8. PubMed ID: 21198706
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Bone and calcium update; diagnosis and therapy of metabolic bone disease update. Guideline for prevention and treatment of osteoporosis update].
    Orimo H
    Clin Calcium; 2011 Dec; 21(12):123-43. PubMed ID: 22133832
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biomechanics of fracture: is bone mineral density sufficient to assess risk?
    McCreadie BR; Goldstein SA
    J Bone Miner Res; 2000 Dec; 15(12):2305-8. PubMed ID: 11127195
    [No Abstract]   [Full Text] [Related]  

  • 51. FRAX® counseling for bone health behavior change in women 50 years of age and older.
    Dunniway DL; Camune B; Baldwin K; Crane JK
    J Am Acad Nurse Pract; 2012 Jun; 24(6):382-9. PubMed ID: 22672490
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fracture assessment tool risk scores in bone density reports do not change physician prescribing behavior for osteoporosis.
    Izuora KE; Alazraki N; Byrd-Sellers J; Tangpricha V; Nanes MS
    Am J Med Sci; 2011 Jul; 342(1):5-8. PubMed ID: 21412137
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessing fracture risk and effects of osteoporosis drugs: bone mineral density and beyond.
    Davison KS; Kendler DL; Ammann P; Bauer DC; Dempster DW; Dian L; Hanley DA; Harris ST; McClung MR; Olszynski WP; Yuen CK
    Am J Med; 2009 Nov; 122(11):992-7. PubMed ID: 19854322
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Japanese Guidelines for the Prevention and Treatment of Osteoporosis (2006 Edition) and its significance].
    Nakamura T
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():29-34. PubMed ID: 18161078
    [No Abstract]   [Full Text] [Related]  

  • 55. [Use of bone densitometry in the framework of prevention and therapy of osteoporosis. Example of a systematic evaluation (health technology assessment)].
    Lühmann D; Kohlmann T; Raspe H
    Z Arztl Fortbild Qualitatssich; 2000 Aug; 94(6):475-81. PubMed ID: 10996937
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of clinical risk factors for osteoporosis and applicability of the FRAX tool in Joinville City, Southern Brazil.
    Silva DMW; Borba VZC; Kanis JA
    Arch Osteoporos; 2017 Dec; 12(1):111. PubMed ID: 29224172
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bone density measurement--a systematic review. A report from SBU, the Swedish Council on Technology Assessment in Health Care.
    J Intern Med Suppl; 1997; 739():1-60. PubMed ID: 9104441
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diagnosis and treatment of osteoporosis.
    Sweet MG; Sweet JM; Jeremiah MP; Galazka SS
    Am Fam Physician; 2009 Feb; 79(3):193-200. PubMed ID: 19202966
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bone mineral density testing: is a T score enough to determine the screening interval?
    Doshi KB; Khan LZ; Williams SE; Licata AA
    Cleve Clin J Med; 2013 Apr; 80(4):234-9. PubMed ID: 23547094
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Utility of DXA screening for diagnosis of osteoporosis in US veterans aged 70 years and older.
    Khatib J; Stote K; Gosmanov AR
    J Investig Med; 2018 Feb; 66(2):298-303. PubMed ID: 28974557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.